ArticleSAGE open medicine2026
Peritoneal effusion as a marker of disease severity in secondary hemophagocytic lymphohistiocytosis: Clinical and immunological insights.
Article in SAGE open medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome with cytokine storm-mediated multiorgan damage. Although serous effusions are frequent complications, the prognostic significance of peritoneal effusion in secondary HLH (sHLH) remains undefined. This study aimed to determine the incidence, clinical and immunological correlates, and prognostic value of peritoneal effusion in sHLH patients. Methods: We retrospectively analyzed 107 adult patients diagnosed with sHLH at the Second Affiliated Hospital of Anhui Medical University between March 2013 and March 2023. Peritoneal effusion was diagnosed based on abdominal ultrasound, computed tomography, or positron emission tomography-computed tomography at initial presentation. Clinical characteristics, laboratory parameters, and lymphocyte subset profiles were compared between patients with and without peritoneal effusion. Logistic regression was used to identify risk factors for peritoneal effusion. Overall survival (OS) was estimated using the Kaplan-Meier method, and independent prognostic factors were assessed using multivariate Cox regression analysis. Results: Peritoneal effusion was found in 24/107 (22.4%) sHLH patients and was associated with lower white blood cell, lymphocyte, monocyte, and platelet counts. Lower monocyte counts, higher direct bilirubin, and distinct immune dysregulation (reduced CD4+ T cells, higher NK cell percentages) were identified as risk factors for peritoneal effusion. Peritoneal effusion correlated with concurrent serous effusions (p < 0.05) and markedly shorter median survival (19 vs. 103 days, p = 0.002). Multivariate analysis identified peritoneal effusion as an independent mortality predictor (HR=1.88; 95% CI 1.09-3.24, p = 0.023). Conclusions: Peritoneal effusion is an independent predictor of mortality in sHLH patients and is associated with a distinct immune profile. Its presence should alert clinicians to a higher risk of death and prompt early, aggressive therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.